List of Posters

A list of moderated posters are available here.

Natural history, epidemiology & risk prediction

P-01
Bobby Chacko: Characterisation of IgA Nephropathy in an Australian Cohort

P-02
Cheng-Hsu Chen: Urinary Galactose-Deficient IgA1 as a Potential Early Biomarker for IgA Nephropathy

P-03
Keita Hirano: KDIGO chronic kidney disease risk category and renal survival in patients with IgA nephropathy

P-04
Shiko Honma: Utility of A/C subclassification of histological grade classification of IgA nephropathy: a Japanese prospective cohort study

P-05
Toshiki Kano: Microscopic hematuria is an early hallmark of IgA nephropathy and an indicator of disease activity

P-06
Sayumi Kawamura: Validation of International risk-prediction tool and its Comparison with the JSN Classification in Japanese Patients with IgA Nephropathy: A Retrospective Cohort Study

P-07
Kirill Komissarov: Serum IgE is biomarker of benign course of IgA nephropathy

P-08
Nicolas Maillard: Clinical Validation of an IgA1 Galactose-Deficient Assay Kit in IgA Nephropathy

P-09
Dita Maixnerova: Outcome of Czech patients with IgA nephropathy

P-10
Laila-Yasmin Mani: Characteristics and outcome of immunoglobulin A nephropathy – a Swiss single center experience

P-11
Masahiro Muto: The clinical impact of glomerular C3 depositions on the severity and treatment responses in IgA nephropathy

P-12
Sasikiran Nunna: Healthcare resource utilization and costs among patients with primary immunoglobulin A nephropathy (IgAN) by proteinuria and kidney function decline in China

P-13
William J. Placzek: Serum galactose-deficient IgA1 levels in patients with IgA nephropathy and healthy controls measured with GalD®, a novel lectin-based enzyme-linked immunosorbent assay

P-14
Anna Popova: Gut Microbiome Features in IgA Nephropathy Patients with Favorable and Unfavorable Prognosis

Paediatric disease

P-15
Luca Antonucci: Alternative budesonide formulation in pediatric IgA Nephropathy as a possible therapeutic option: a case series

P-16
Luca Antonucci: Secondary IgA Nephropathy in the context of disseminated tuberculosis: a pediatric case report

P-17
Stephen Nolan: An open-label phase 3 study of ravulizumab in pediatric immunoglobulin A nephropathy or immunoglobulin A vasculitis-associated nephritis

P-18
Liping Rong: Exploration influence of the intensity of renal immune cell infiltration on clinicopathological features and prognosis in children with IgA nephropathy

P-19
Xiaohong Zheng: Correlation of capillary loop IgA deposition with clinicopathological features in pediatric IgA nephropathy

P-20
Xuhui Zhong: Nefcon Use in Pediatric IgA Nephropathy: Three Case Reports

IgA vasculitis

P-21
Miho Miyauchi: A comparative study of clinical and pathological differences between adult-onset IgA vasculitis and IgA nephropathy

Pathogenesis

P-22
Altynay Balmukhanova: When it is not IgA nephropathy: a case highlighting the diagnostic value of renal biopsy

P-23
Yu-Hsuan Huang: Combination of a mouse monoclonal antibody and a GalNAc-specific lectin for monitoring of IgA nephropathy

P-24
Kensuke Joh: The Role of T Nodule in the Tonsil-Glomerular Axis in Patients with IgA Nephropathy: A Retrospective Cohort Study

P-25
Shuk-Man Ka: Competitive Binding Between IgA and IgG Autoantibodies to Gd-IgA1 Derived from the Same IgA Nephropathy Patient

P-26
Eriko Kosuge: Analysis of renal lymph node revealed the presence of IgG+ germinal center B cells in IgA nephropathy model mice

P-27
Tzu-Yu Liu: Targeting human IgA autoantibodies and galactose-deficient IgA1 antigen to unravel their pathogenic roles in IgA nephropathy

P-28
Lea Novak: Kidney injury and colocalization of complement C3, IgA, and IgG in glomerular immune-complex deposits in patients with IgA nephropathy and IgA vasculitis with nephritis

P-29
Sandra Romero-Ramirez: Evaluation of IgA1 and IgA2 coating patterns of the gut microbiota of IgA Nephropathy patients

P-30
Francesco Paolo Schena: Longitudinal blood single-cell RNA sequencing study in IgAN patients from the randomized cligan trial (RCT)

P-31
Kazuo Takahashi: Dextran sulfate sodium-induced chronic inflammatory colitis reduces intestinal propionate and causes glomerular IgA-IgG deposition in HIGA mice

P-32
Hernan Trimarchi: Moving from the four- to the five-hit hypothesis in IgA nephropathy. A proposal based on novel pathophysiological concepts with potential therapeutic implications

P-33
Xinfang Xie: Exploration of the IgA1 O-glycoforms profile and pathogenic IgA-complex compositions by mass spectrum in IgA nephropathy

Treatment

P-34
Ryousuke Aoki: Single-center outcomes and clinical features of persistent urinary abnormalities after tonsillectomy and steroid pulse therapy in IgA nephropathy

P-35
Jonathan Barratt: AFFINITY study: 1 year results of atrasentan in IgAN in patients with UPCR <1 and ≥1g/g

P-36
Jonathan Barratt: ALIGN post-hoc analyses: Reduction in proteinuria with atrasentan across subgroups by MEST-C score, baseline hematuria and baseline UPCR

P-37
Jonathan Barratt: Changes in proteinuria and kidney function in subgroups of patients with IgAN defined by baseline Gd-IgA1 levels in a Phase 1/2 study of zigakibart

P-38
Jonathan Barratt: Effect of iptacopan discontinuation on proteinuria and complement biomarkers in patients with immunoglobulin A nephropathy (IgAN): a post hoc analysis from a Phase II trial

P-39
Jonathan Barratt: Effects of nefecon on Hits 1, 2, and 3 of the pathogenic cascade of IgA nephropathy: a full NefIgArd analysis of exploratory biomarkers

P-40
Jonathan Barratt: Efficacy of nefecon by baseline eGFR deciles: a subanalysis from the NefIgArd trial of daily nefecon 16 mg or placebo in addition to supportive care for patients with biopsy-confirmed primary IgAN

P-41
Jonathan Barratt: Safety, tolerability, and efficacy of mezagitamab (TAK-079) as add-on to standard-of-care therapy in primary IgA nephropathy: Week 48 results from a phase 1b study

P-42
Jonathan Barratt: Zigakibart-treated patients with IgAN achieved high rates of proteinuria remission and stable eGFR over 76 weeks in a Phase 1/2 study

P-43
Shasha Chen: Budesonide enteric capsules for IgA nephropathy with hepatitis B virus infection: Two cases

P-44
Shasha Chen: Efficacy and Safety of Nefecon in IgA Nephropathy: A 6-Month Retrospective Cohort Study

P-45
Ming Cheng: Beyond Nine Months: Real-World Efficacy and Safety of Extended Nefecon Therapy in IgA Nephropathy

P-46
Chee Kay Cheung: Sparsentan as first-line treatment of incident patients with IgA nephropathy: An interim analysis of the SPARTAN trial evaluating efficacy and cardiovascular risk variables

P-47
Ming Fang: Efficacy and Safety of Finerenone in Immunoglobulin A Nephropathy: A 12-months Real-World Observational Study

P-48
Ming Fang: Nefecon Treatment in Patients with Primary IgA Nephropathy and Renal Insufficiency: A 6-Month Observational Study

P-49
Jürgen Floege: Felzartamab for IgA nephropathy: final results of the IGNAZ study

P-50
Nozomi Kadota: Is IgA nephropathy a curable disease? ~case series of repeat biopsy~

P-51
Richard Lafayette: Impact of sustained UPCR reduction on eGFR over 2 years: a secondary analysis from the NefIgArd trial of daily nefecon 16 mg or placebo in addition to supportive care for patients with biopsy-confirmed primary IgAN

P-52
Richard Lafayette: Impact of time since diagnosis on eGFR and UPCR changes over time with nefecon: a subanalysis from the NefIgArd trial of daily nefecon 16 mg or placebo in addition to supportive care for patients with biopsy-confirmed primary IgAN

P-53
Richard Lafayette: UPCR response at 12 months in patients with IgAN receiving nefecon vs placebo: analysis of NefIgArd trial data

P-54
Selvin Sundar Raj Mani: Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-Proven IgAN: Multi-center, Multi-arm and Multi-stage - Design Innovations and Operational Feasibility in Resource-Limited Settings

P-55
Stephen Nolan: Spot and 24-hour assessments of proteinuria and albuminuria in IgA nephropathy: A prespecified analysis of the SANCTUARY trial

P-56
Sasikiran Nunna: Treatment patterns and healthcare resource utilization among adults with primary IgA nephropathy (IgAN) in China: a longitudinal retrospective cohort study from a multi-province registry

P-57
Vlado Perkovic: Evaluating sibeprenlimab for Patients With IgA Nephropathy: Results From a Prespecified Interim Analysis of the Phase 3 VISIONARY Study

P-58
Dana V. Rizk: A mechanistic biopsy study of the effect of iptacopan on immunopathology in patients with IgA nephropathy (IgAN)

P-59
Dana V. Rizk: Safety and efficacy of iptacopan in patients with IgA nephropathy (IgAN) with baseline eGFR 20-<30 mL/min: Phase 3 APPLAUSE-IgAN subcohort results

P-60
Millie Shah: Felzartamab durably reduces disease relevant biomarkers through targeting of CD38+ plasma cells and plasmablasts, the upstream drivers of IgA nephropathy

P-61
Sydney CW Tang: Concomitant sparsentan (SPAR) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in adults with IgA nephropathy (IgAN) in the phase 2 SPARTACUS trial

P-62
Xiaoyan Xiao: Early Intervention with Budesonide Enteric-Coated Capsules in IgA Nephropathy: 2 Case Demonstrating Reduced Proteinuria and Stabilized Renal Function

P-63
Lan Yang: The efficacy of Nefecon in the treatment of IgA nephropathy and IgA vasculitis nephritis: first-in-pediatrics case series

P-64
Junjun Zhang: Efficacy and Safety Profile of Nefecon in 26 Chinese Patients with IgA Nephropathy: A Real-World Observational Study

Transplantation

P-65
Guisen Li: Telitacicept Treatment for Recurrent IgA Nephropathy after Kidney Transplantation

Last update on 8 September 2025.

The programme might be subject to necessary changes.